Whalesbook
WHO ne THSTI ko banaya global biomanufacturing training ka star!
Yaar, ye bahut badi baat hai. WHO ne Faridabad wale Translational Health Science and Technology Institute (THSTI) ko ek regional biomanufacturing training center banne ka decision liya hai. Ye India ke budding biotechnology sector ke liye ek dum game-changer ho sakta hai. Ye designation WHO ki us global koshish ka hissa hai jahan vital health technologies ki production mein jo skills ki kami hai, use poora kiya ja sake. Aur mazedaar baat ye hai ki South-East Asia Region ke liye THSTI hi akela center hoga! Isse India ka biomanufacturing mein leadership ka goal aur bhi strong hoga, aur sector 2030 tak $300 billion tak pahunch sakta hai. Poora global biomanufacturing market bhi tezi se badh raha hai, jismein next-gen segments akele $57.6 billion tak pahunch sakte hain 2035 tak, aur overall biotech market $4.3 trillion cross kar sakta hai 2034 tak.
Aur India mein already Biocon Limited jaise bade players hain. May 2026 tak, Biocon ka market cap lagbhag ₹582.46 billion tha aur P/E ratio 40.34 se 98.61 ke beech tha. Analysts ne Biocon ke liye target price ₹422.19 set kiya hai. Ab THSTI ke is role se skilled workforce badhegi, jisse India ka biopharmaceutical output, jo 2024 mein $101.5 billion tha aur 2033 tak $297.2 billion hone ka forecast hai, use aur boost milega.
Global skills ki kami ko kaise door karenge?
Ye WHO ka Biomanufacturing Workforce Training Initiative jo 2023 mein start hua tha, uska main aim hi yehi hai ki skills ki global shortage ko fix kiya jaaye. COVID-19 pandemic ne dikha diya tha ki global supply chains kitni weak ho sakti hain. Is initiative ke through, aur THSTI jaise centers ko establish karke, WHO chahti hai ki manufacturing capabilities geographically spread ho aur robust bane. Isse Low- and Middle-Income Countries (LMICs) ko vaccines aur biotherapeutics locally produce karne mein help milegi.
THSTI khud bhi dengue aur SARS-COV-2 viruses, aur antimicrobial resistance jaise critical areas par focus karega. Ye Ireland ke NIBRT aur China ke Peking University jaise dusre centers ke saath bhi kaam karega. India ki apni policies, jaise BioE3 policy jo 2030 tak $300 billion ka bioeconomy target rakhti hai, aur Bio-RIDE scheme jo R&D aur biomanufacturing ko support karti hai, ye sab milkar ek strong base bana rahe hain. India ka R&D spending bhi lagbhag $188 billion hai early 2026 mein, jo ise world mein third position par rakhta hai. Ye milkar kaam karne ka tareeka training gaps ko bharne mein madad karega, jabki pehle advanced training mehngi aur sirf developed countries mein milti thi.
Aage kya challenges hain?
Abhi bhi kuch challenges hain. Regulatory issues, jaise CDSCO aur DBT ke checks, delays kar sakte hain. Infrastructure aur funding mein bhi differences hain, jo policies se address ho rahe hain par phir bhi progress slow ho sakta hai. Aur jab technology itni tezi se badh rahi hai, toh regulatory system ko uske saath chalna mushkil ho sakta hai.
THSTI ki success international cooperation par depend karegi. Ireland aur China jaise developed countries se competition bhi ek bada factor hai. Global biopharmaceutical industry mein bhi costs badh rahi hain aur pricing rules change ho rahe hain, jo investment par asar daal sakte hain.
India ki badhti ambitions!
Lekin ye WHO designation India ke liye ek strategic endorsement hai jo BioE3 policy jaise goals ko support karta hai. Isse India ke biomanufacturing chain mein professionals ka skill level aur number definitely badhega. Isse synthetic biology, biopharmaceuticals, aur advanced diagnostics jaise fields mein expertise badhegi. Jaise jaise countries strong manufacturing capabilities chahti hain, India, THSTI ke through, global health security mein ek vital partner ban raha hai. Ye practical training India ko $300 billion ki bioeconomy tak pahunchne mein madad karegi. International standards aur India ke domestic infrastructure ka combination innovation ko badhayega, investment attract karega aur India ki position global network mein strong karega.